ArticleFrontiers in oncology2026
Explainable incremental-value analysis of apparent diffusion coefficient and arterial spin labeling radiomics for ATRX status prediction in glioblastoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alpha-thalassemia/mental retardation syndrome X-linked (ATRX) mutation is an uncommon but biologically relevant molecular feature in glioblastoma (GBM), linked to tumor heterogeneity, DNA damage response pathways, and treatment-relevant biology. Noninvasive prediction of ATRX status remains challenging, and the incremental value of physiologic MRI beyond structural imaging is unclear. Methods: We analyzed 106 patients with GBM with available ATRX status and complete multiparametric MRI. Four radiomics models were compared. Model 1 used structural MRI features from contrast-enhanced T1-weighted, T2-weighted, and FLAIR images, along with age and sex. Model 1A additionally incorporated ADC and ASL-CBF radiomic features. Models 1B and 1C served as ablation models isolating the individual contribution of ADC and ASL-CBF, respectively. Six machine-learning classifiers were evaluated using stratified cross-validation, class-imbalance-aware metrics, bootstrapped confidence intervals, paired DeLong testing, and SHAP explainability. Results: The best structural model achieved an ROC-AUC of 0.721, a PR-AUC of 0.322, and a sensitivity of 0.737. Model 1A demonstrated statistically significant improvements, achieving an ROC-AUC of 0.753, a PR-AUC of 0.364, and a sensitivity of 0.947. Across classifiers, ADC and ASL improved discrimination in five of six classifiers (DeLong, p<0.05). SHAP analysis showed that age remained the dominant predictor, while ASL- and ADC-derived texture features contributed meaningful physiologic information. Discussion: ADC and ASL-CBF radiomics provide a modest but statistically significant incremental value for ATRX prediction in GBM. These findings support further validation of functional MRI sequences as a complementary radiogenomic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.